Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Diltiazem on MK-4318 Pharmacokinetics
NCT06692647Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MK-4318 in pain, sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to Infinity, Area Under the Concentration-Time Curve from Time 0 to 24 hours and 7 more. Started Feb 2024; status: completed.
02
Drugs
MK-4318
03
Conditions
pain
Beyond the preview
Go deeper on NCT06692647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692647.